Tag Archives: Healthcare

RESI JPM 2026 Investor Panels Announced 

16 Dec

Attendees voted with their RESI Cash alongside judges’ scores to determine this year’s winners.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the investor panelists for RESI JPM 2026, taking place January 12–13 during JPM Healthcare Week. Across two full days, RESI JPM will bring together active investors, strategic partners, and industry leaders for focused discussions on the funding environment, partnership strategies, and emerging opportunities across life sciences and healthcare. 

RESI investor panels are designed to provide founders and executives with direct insight from decision-makers who are actively deploying capital, forming partnerships, and shaping the future of the industry. Each panel features experienced investors and strategics sharing candid perspectives, followed by opportunities to continue conversations through RESI’s structured partnering platform. 

Investor Speakers on Day 1 (January 12)


Sharon Chan
Johnson & Johnson Innovation – JLABS Asia Pacific
Irene Cheong
A*STAR
Ansbert Gadicke
MPM BioImpact

Dushyant Pathak
Autobahn Labs
Andrew Krowne
Dolby Family Ventures
Robert Balfour
ALSA Ventures

Rick Berenson
Mass Medical Angels
Gunes Bozkurt
Beiersdorf
Jian Cao
Medtronic

Jeff Chu
Features Capital
Karen Chu
Harvest Integrated Research Organization (HiRO)
Rod Cotton
2Flo Ventures

Juan Cueva
Johnson & Johnson Innovation
Bettina Ernst
BERNINA BioInvest
Jack Florio
NuFund Venture Group

Nirdesh Gupta
Cedars-Sinai Technology Ventures
Karen Harris
Alzheimers Drug Discovery Foundation
Uplaksh Kumar
Foresite Capital

Ken Lin
ABIES Capital
Michael Loftus
PoC Capital
Brianna McDonald
Ecosystem Venture Group

Swati Mehta
25BIO
Ahmed Mousa
LAFANA
Mahesh Narayanan
Neuvation Ventures

Kenny Nova
Mid Atlantic Bio Angels
Jessica Owens
INITIATE Ventures
Jojo Platt
Corundum Neuroscience

Steven Saltzstein
FORCE Family Office
Garth Smith
Ontario Brain Institute
James Spann
Boyd Street Ventures

Jessica Tam
Baxter Healthcare
Lee Chuan Teck
Enterprise Singapore
Varun Turlapati
Chaanakya Capital 

Investor Speakers on Day 2 (January 13)


Friedemann Janus
Bayer
Jiaping Gu
Takeda Ventures
David Berry
Averin Capital

Ekaterine Kortkhonjia
Johnson & Johnson Innovation
Nick Naclerio
Illumina Ventures
Eric Schaefer
March of Dimes

Marc Appel
Pacific Bridge NY
Anjan Aralihalli
Raya Therapeutic
Yaron Daniely
aMoon Fund

Miriam Dong
ID3 Ventures
Cristina Escoda
Tachyon Ventures
Yinghong Gao
Viva BioInnovator

Gary Gershony
BayMed Venture Partners
Tom Gibbs
Debiopharm Innovation Fund
Rohit Jain
HBS Alumni Angels of Northern California

Sai Jasti
Bayer
Anula Jayasuriya
Kidron Capital
Gautam Kainth
TCP Health Ventures

Jin Lee
Oxonian Ventures
Brian Miglionico
Agios Pharmaceuticals
Ralph Morales III
Aquillius Ventures

Stephanie Oestreich
Myeloma Investment Fund
Donna Parr
Cross-Border Impact Ventures
Bibi Sattar Marques
Buenavista Equity Partners

Takehiko Sawabe
Beyond Next Ventures
Venkat Srinivasan
Innospark Ventures
Anthony Vallance-Owen
We Venture Capital

Chensu Wang
Yonjin Venture
Chris Yoo
Xcellerant Ventures
Qing Zhang
LDV Partners

Register for RESI JPM 2026 

RESI JPM 2026 offers more than panels. Attendees gain access to curated investor meetings through RESI’s partnering system, targeted networking, and programming designed to support meaningful connections during one of the most important weeks in healthcare investment. 

Register for RESI JPM 2026

Tags: , , , , , , , , , , , , , ,

Innovator’s Pitch Challenge Winners Announced at RESI London 2025 

9 Dec

Attendees voted with their RESI Cash alongside judges’ scores to determine this year’s winners.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the winners of the Innovator’s Pitch Challenge (IPC) at RESI London 2025. This year’s competition featured 26 participating companies, each showcasing early-stage technologies to a panel of experienced investors and an audience of global attendees. 

The IPC remains a cornerstone of every RESI conference, allowing founders to present to a coordinated group of investors who provide interactive questions and valuable feedback. Attendees cast votes using their RESI Cash, which was combined with judges’ assessments to select this year’s top companies. 

Congratulations to the RESI London 2025 IPC winners: 

These companies stood out among a highly competitive group of innovators spanning therapeutics, medical devices, diagnostics, and digital health. 

Congratulations, as well, to the companies from each session who received the highest judges scores:  

Looking ahead: Applications are now open for Life Science Nation’s next European conference, taking place in Portugal on March 23, 2026. Companies interested in pitching can apply here. 

Apply to Pitch at RESI Europe

Tags: , , , , , , , , , , , ,

You are Invited! Join Kansai Life Science Accelerator Program (KLSAP) Demo Day at RESI JPM 2026 

2 Dec

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Join us for a special showcase of Japan’s most promising early-stage life science innovators at the KLSAP 2025 Demo Day, presented by the Kobe Biomedical Innovation Cluster (KBIC). This dynamic session will feature three finalists from the Kansai Life Science Accelerator Program alongside eight KBIC startups and alumni. Companies will deliver focused pitches highlighting new advances in therapeutics, medical platforms, diagnostics, and digital health, followed by live Q&A with global investors.

Hosted during RESI JPM 2026, this session is an excellent opportunity for investors, BD teams, and innovation scouts looking to connect with high-potential Japanese technologies poised for global expansion.

📅 January 13, 12:00–2:00pm PST
📍 Golden Gate C3 Room, Marriott Marquis San Francisco

Agenda: 
12:00–12:03 Opening – KLSAP Overview

12:03–12:45 KLSAP 2025 Demo Day 
Featuring 3 Finalist Companies (7 minute pitch + 6 minute Q&A with investor panel) 

C-Biomex GeneMedicine ixgene

12:45–12:50 KLSAP 2025 Demo Day Closing – KBIC Introduction 

12:50–1:53 KBIC Startups and Alumni Speed Pitches 
Featuring 8 startups (5 minute pitch) 

aceRNA-Technologies Celaid CellFiber
CynosBio FerroptoCure linqmed
quadlytics

1:53–2:00 KBIC Session Closing 

RSVP to Attend

Tags: , , , , , , , , , , , ,

RESI London Innovator’s Pitch Challenge Finalists 

18 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge showcases early-stage companies developing breakthrough technologies across key sectors of life sciences.

The Innovator’s Pitch Challenge (IPC) returns to RESI London with a full lineup of pioneering startups presenting across multiple themed sessions. Each finalist will pitch to panels of relevant investors and industry leaders, gaining practical feedback and creating valuable connections with partners actively seeking new technologies. The IPC provides fundraising companies with a platform to elevate their visibility and engage with a global network of investors and strategics.

If you are attending RESI London, make time to see these pitches and meet the founders throughout the day. Delegates participating in partnering can also schedule one-on-one meetings with the finalists. Full event and registration details are available at resiconference.com/resi-london.

Meet the RESI London Innovator’s Pitch Challenge Finalists

Session 1 | 9:00 – 10:00 AM | Therapeutics

Session 2 | 10:00 – 11:00 AM | Diagnostics Tools & Platforms

Session 3 | 11:00 AM – 12:00 PM | Therapeutics

Session 4 | 1:00 – 2:00 PM | Therapeutics & Medical Devices

Session 5 | 2:00 – 3:00 PM | Therapeutics

Session 6 | 3:00 – 4:00 PM | Medical Devices

Session 7 | 4:00 – 5:00 PM | R&D and Enabling Technologies
Register for RESI London

Tags: , , , , , , , , , , , ,

From Lab to Market: Why Life Science Companies Are Drawn to Singapore 

12 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

LSN is proud to announce our partnership with Enterprise SG for RESI JPM 2026, to foster meaningful conversations on global life science innovation, investment and cross-border collaboration. Learn how Singapore is a dynamic launchpad for innovation and home to cutting-edge startups ready to collaborate on your next breakthrough. Join us at our upcoming panel on January 12 to find out more! 

As global healthcare challenges intensify, innovative biomedical technologies from Asia are stepping up to drive change, translating life science research into real-world solutions. Increasingly, investors, corporates, startups, and healthcare systems around the world are seeing the urgency in bridging the East and West to improve healthcare outcomes and deliver value-based care.

Singapore, located at the heart of Asia, is a dynamic hub for biomedical innovation, driven by a strong network of global investors, researchers, mentors, and innovators. With decades of sustained government investments and a robust talent pipeline from world-class universities and research institutes, it is home to over 500 biomedical and medtech companies. The ecosystem has attracted venture capitalists and venture builders like MPM BioImpact, Polaris Partners, and Flagship Pioneering, as well as global pharma leaders such as Pfizer, Roche, and Johnson & Johnson. These players work closely with government agencies, like Enterprise Singapore, that drive startup development, provide patient funding, expertise, infrastructure, and networks crucial for producing globally competitive solutions.

Singapore’s strategic position as a bridge between Asian and global markets enables it to play an outsized role in driving biomedical advancements. This works both ways, as a gateway for global companies to access the growing opportunities in Asia, and as a springboard for regional companies to expand worldwide. For example, through partnerships with healthcare organisations like Cedars-Sinai and Mayo Clinic in the US, Enterprise Singapore supports Singapore startups to test and scale their solutions in overseas markets, facilitating a bi-directional flow of innovation to improve healthcare for communities.

Join Enterprise Singapore at the ‘Asia Cross Border Investments Panel’ to explore how cross-border capital, talent, and technologies are converging to drive breakthroughs in precision medicine, innovative therapies, and next-generation diagnostics. The panel will take place on January 12, 2026, from 11:00 am to 12:00 pm at RESI JPM by LSN, held at the Marriott Marquis, San Francisco. Learn from prominent industry leaders how transcontinental partnerships, including those with Singapore, are shaping the future of healthcare innovation – from discovery to global commercialisation.

To join the conversation, please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.

Tags: , , , , , , , , , , ,

Kobe Biomedical Innovation Cluster (KBIC) Joins RESI JPM 2026 as Gold Sponsor

28 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is proud to announce that the Kobe Biomedical Innovation Cluster (KBIC) will serve as a sponsor for RESI JPM 2026, continuing its mission to promote innovation, entrepreneurship, and global collaboration in life sciences. 

As part of this sponsorship, KBIC will host the Kansai Life Sciences Accelerator Program (KLSAP) 2025 Demo Day at RESI JPM 2026 on Tuesday, January 13, 12:00 – 2:00pm PT at the Marriott Marquis San Francisco. The Demo Day will feature 3 startups that are part of the KLSAP 2025 Cohort as well as other member companies of KBIC, to be announced as the event approaches. This initiative will provide participating companies with global exposure, strategic investor connections, and the opportunity to pitch to an international audience of early-stage investors and strategic partners across life science and healthcare sectors.

Interested in joining and receiving updates on the KLSAP 2025 Demo Day? Please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.  

Introduction of Kobe Biomedical Innovation Cluster (KBIC)
Located in the heart of Kobe, Japan, the Kobe Biomedical Innovation Cluster is one of the nation’s leading ecosystems dedicated to the advancement of biomedical research and commercialization. With more than 340 organizations, including research institutes, hospitals, and life science companies, KBIC plays a vital role in bridging academia, government, and industry to accelerate innovation and improve global health outcomes. 

By partnering with RESI JPM 2026, KBIC aims to strengthen international collaboration and support Japanese startups seeking to expand their networks and raise global awareness for their technologies. Through this continued engagement, KBIC and LSN will work together help founders access global capital and strategic resources to advance from concept to commercialization. 

About Kansai Life Sciences Accelerator Program (KLSAP)
Powered by KBIC, the Kansai Life Sciences Accelerator Program (KLSAP) supports early-stage life science and healthcare startups in the Kansai region through tailored mentorship, commercialization guidance, and access to global investor networks. 

The 2025 KLSAP Cohort will participate in RESI JPM 2026 to present their innovations to a diverse investor audience, gain valuable feedback, and establish partnerships that can help drive their technologies toward global markets. The cohort’s participation exemplifies KBIC’s commitment to supporting international expansion and facilitating cross-border collaboration in life sciences. 3 companies have been selected for this year’s KLSAP Cohort, with descriptions of each company added below:

C-Biomex
Founded in 2017, C-Biomex is a bio-venture dedicated to advancing novel theranostics using its proprietary peptide discovery platform, CUS™. The platform enables identification of peptides with high stability and specificity through a three-step process involving a high-purity library, an innovative screening protocol that minimizes background interactions, and direct sequencing via a proprietary algorithm. C-Biomex focuses on radiopharmaceutical development, positioning itself at the intersection of diagnostics and therapeutics to accelerate peptide-based solutions for global biomedical applications.

GeneMedicine
GeneMedicine, founded in 2014 and based in Seoul, develops oncolytic viruses engineered to selectively replicate in and kill cancer cells while stimulating an anti-tumor immune response. Its GM-oAd platform is designed for systemic delivery of oncolytic adenoviruses with enhanced tumor specificity, immune activation, and ability to overcome physical tumor barriers. In addition to its therapeutic pipeline, GeneMedicine is expanding into CDMO services and novel drug-delivery systems, building a sustainable and diversified business model.

iXgene
iXgene is a Japanese life sciences company focused on developing therapies for intractable diseases using genome editing and induced pluripotent stem (iPS) cell technology. Its proprietary platform combines advanced genome editing tools, such as CRISPR, with iPS-derived therapeutics targeting indications including malignant brain tumors and brain injury. iXgene collaborates with academic institutions and pharmaceutical partners to translate next-generation regenerative and gene therapies into the clinic, aiming to address high-unmet-need central nervous system diseases. 

LSN and KBIC invites all investors, industry leaders, and innovators to meet the KLSAP 2025 Cohort at RESI JPM 2026. Together, they will continue to advance global innovation and foster meaningful connections across the life sciences ecosystem. 

Register for RESI JPM

Tags: , , , , , , , , , ,

Confirmed Investors at RESI London 2025 

21 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is thrilled to announce the confirmed investors for RESI London 2025, taking place on December 4, at King’s Fund, 11 Cavendish Square, with virtual partnering on December 8–9. This premier event connects early-stage life science companies with a diverse array of global investors, facilitating meaningful partnerships and funding opportunities.

Meet the Confirmed Investors

RESI London 2025 will feature a robust lineup of investors spanning various sectors within the life sciences industry. Confirmed investors include:

This diverse group of investors represents a broad spectrum of interests, from pharmaceutical giants to specialized venture capital firms, ensuring that attendees have access to a wealth of expertise and potential funding sources.

Why Attend RESI London 2025?

RESI London 2025 provides an exceptional platform for early-stage companies to engage directly with top-tier investors across the life sciences industry, present innovations to a panel of esteemed judges in the Innovator’s Pitch Challenge (IPC), and receive valuable feedback. Attendees will have the opportunity to expand their network by building relationships with potential partners, collaborators, and industry experts, while also continuing discussions and meetings through virtual partnering on December 8–9, extending their reach and maximizing opportunities.

Whether you’re seeking funding, partnerships, or strategic alliances, RESI London 2025 provides the resources and connections necessary to propel your venture forward.

Register for RESI London >>

Tags: , , , , , , , , , ,

← Older Entries